News
Calm Business bolsters workplace offering to address ‘urgent’ employee mental health needs
The platform adds new integrations and features to support HR and benefit leaders
Calm Business, Calm’s workplace mental health platform, has announced a suite of product updates to “uplevel” employer mental health strategies.
Calm Business launched in 2020 to bring workplaces Calm as a benefit for employees and provide people leaders analytics, workshops and customer service as they navigated supporting employee mental health.
Now, the platform expands its product to address what is describes as critical pain points that have emerged for HR, benefits and business leaders and help them build offerings for their workforce needs.
Employee engagement and overall wellbeing are low with many employees quietly quitting. Gallup has found only 23 per cent of employees are thriving at work with the other 77 per cent noting they are not engaged or actively disengaged.
Even more alarming – the impact isn’t solely on the individual employee – people leaders are feeling the direct impact, with 98 per cent experiencing burn out trying to support their teams.
Additionally, research has shown one in three working women experience symptoms of depression or anxiety, with many fearing to take time off.
“We know people leaders are managing more than ever, all while trying to keep employee well-being high,” said Calm president, Alex Will.
“Our Calm Business team is continually evolving our product to support customers as they build strategies unique to their workforce to increase productivity and employee happiness.”
“Today’s new product release was directly informed by customer feedback looking for more personalised and customised tools.”
The new features will be available for employers with 101+ employees through Calm Business’ Enterprise Plan and include in-app collections of Calm content to address organisation’s mental health challenges, mental health resources into employees’ workdays through integrations with tools like Zoom as well as employee check-ins.
Scott Brown, group employee experience manager at Environmental Resources Management (ERM), said: “The new Calm Business features provide impactful insight into how we can respond best to our employees to support their mental health.
“The new offerings help us add to our benefits and allow us to take more informed and personalised steps to support our people.”
Calm Business currently supports more than 3,000 organisations in helping them improve employee mental health and wellbeing.
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Wellness3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Hormonal health5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







Pingback: Is your healthcare organisation as safe and high-quality as you think? - FemTech World